Modern on Tuesday said its vaccine targeting respiratory syncytial virus was effective in preventing disease in the elderly.
In keeping with the Boston Biotech Company, the vaccine was 83.7% effective in preventing lower respiratory disease, defined as two or more symptoms, in people 60 years of age and older. It was 82.4% effective in preventing lower respiratory disease with three or more symptoms.
In keeping with Moderna, no safety concerns were identified during the clinical trial of the vaccine. In keeping with the company, safety and efficacy data from the study shall be published in a peer-reviewed journal. Roughly 37,000 people in 22 countries participated in the clinical trial.
Moderna said it plans to use for approval from the Food and Drug Administration in the first half of this 12 months. There may be currently no FDA-approved RSV vaccine.
Moderna’s shares rose nearly 7% in prolonged trading.
![Why does everyone seem sick](https://image.cnbcfm.com/api/v1/image/107144126-GettyImages-1236879581.jpg?v=1668106588&w=750&h=422&vtcrop=y)
In keeping with the Centers for Disease Control and Prevention, RSV infections kill 6,000 to 10,000 elderly people every year and cause 60,000 to 120,000 hospitalizations.
America experienced a particularly hard RSV season amongst children and the elderly in the fall as the public largely discontinued public health measures implemented in response to the Covid-19 pandemic, resembling masks and social distancing.
Moderna’s RSV vaccine uses the same messenger RNA technology as Covid’s successful vaccines. The Covid vaccine has made Moderna a world brand and generated windfall profits, nevertheless it stays the company’s only product on the market, and demand is waning.
The Boston-based biotech company is facing mounting pressure to show that other products in its pipeline will successfully enter the market. Morgan Stanley estimates the adult RSV vaccine market to be between $7 billion and $10 billion.